Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2009-04-06
2011-10-04
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S248100, C514S393000
Reexamination Certificate
active
08029808
ABSTRACT:
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5736146 (1998-04-01), Cohen
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5869058 (1999-02-01), Cohen
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6136315 (2000-10-01), Srivastava
patent: 7132109 (2006-11-01), Srivastava
patent: 2002/0037290 (2002-03-01), Armen
patent: 2002/0172682 (2002-11-01), Srivastava
patent: 2002/0192230 (2002-12-01), Srivastava
patent: 2004/0022796 (2004-02-01), Srivastava
patent: 2004/0253228 (2004-12-01), Srivastava
patent: 2005/0221395 (2005-10-01), Zabrecky et al.
patent: 2006/0093612 (2006-05-01), Srivastava
patent: 2835746 (2003-08-01), None
patent: WO 94/14976 (1994-07-01), None
patent: WO 95/34638 (1995-12-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 99/09030 (1999-02-01), None
patent: WO 99/49881 (1999-10-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 00/54839 (2000-09-01), None
patent: WO 01/34607 (2001-05-01), None
patent: WO 01/91787 (2001-06-01), None
patent: WO 01/77107 (2001-10-01), None
patent: WO 02/11669 (2002-02-01), None
patent: WO 02/22133 (2002-02-01), None
patent: WO 02/18608 (2002-03-01), None
patent: WO 02/32923 (2002-04-01), None
patent: WO 02/34205 (2002-05-01), None
patent: WO 03/092624 (2003-05-01), None
Abstract of Hwang et al (PAACR, Mar. 2002, vol. 43, abstract No. 3909).
U.S. Appl. No. 60/223,133, filed Sep. 18, 2000, Armen.
U.S. Appl. No. 60/377,483, filed May 2, 2002, Srivastava.
U.S. Appl. No. 60/377,484, filed May 20, 2002, Srivastava.
U.S. Appl. No. 09/693,643, filed Oct. 20, 2000, Srivastava.
U.S. Appl. No. 10/126,368, filed Apr. 19, 2002, Srivastava.
U.S. Appl. No. 10/131,937, filed Apr. 25, 2002, Srivastava.
U.S. Appl. No. 10/131,961, filed May 1, 2003, Srivastava.
No Author listed. Biologic Therapy of Cancer, J.B. (de Vita et al., ed., J.B. Lippincott Company, Philadelphia, PA 1995) pp. 668-689 and 803-816.
No Author listed. Chronic Myeloid Leukemia Trialists' Collaborative Group, 1997, J. Natl. Cancer Inst. 89(2):1616-1620.
No Author Listed. NLM Gateway Concept, downloaded from the Web Mar. 16, 2008.
Almand et al. 2001, Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, J. Immunol. 166(1):678-689.
Anderson P. et al. 1994, Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins, Infect. Immun. 62(6):2536-2544.
Anthony et al. 1999, Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion moleculs, Vaccine 17(4):373-383.
Asea et al. 2000 HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine, Nature Medicine 6:435-442.
Banchereau et al. 1998 Dendritic cells and the control of immunity Nature 392:245-252.
Barbour et al. 2001, Imatinib for chronic myeloid leukemia: a NICE mess, The Lancet, Lancet Limited, London, GB vol. 358(9292), p. 1478.
Barrios et al. 1994 Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and Dna K proteins requires cross-linking with antigen, Clin. Exp Immunol. 98(2):229-233.
Barrios et al 1992, Mycobacterial heat-shock proteins as carrier molecules II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming, Eur. J. Immunol. 22(6):1365-1372.
Basu, S. et al. 2001 CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin, Immunity 14(3):303-313.
Basu et al. 2000, Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway, Int. Immunol. 12(11):1539-1546.
Basu S. et al. 1999, Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity, J. Exp Med. 189(5):797-802.
Berke et al. 2000, Peptides spanning the junctional region of both the abl/bcr and the bcr/abl proteins bind common HLA class I molecules, Leukemia 14:419-426.
Bettelheim and March, Introduction of General Organic and Biochemistry 2nd ed. W.B. Saunders Company, New York, NY 1988, Chapter 11, p. 270-299.
Binder et al. 2001, Adjuvanticity of alpha 2-macroglubolin an independent ligand for the heat shock protein receptor CD91, J. Immunol. 166(8):4968-4972.
Binder et al. 2000, CD91: a receptor for heat shock protein gp96, Nat. Immunol. 1(2):151-155.
Birkenmeier, G. 2001, Targeting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin, Mod. Asp. Immunobiol. 2(1):32-36.
Blachere et al., 1997, Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity, J. Exp. Med. 186(8): 1315-1322.
Blander et al. 1993, Major cytoplasmic membrane protein ofLegionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires disease, J. Clin. Invest. 91(2):717-723.
Bortin et al., 1987, “HLA Associations With Leukemia,” Blood 70(1): 227-232.
Breoler et al., 1999 In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins, J. Immunol. 162:3141-3147.
Carlo-Stella et al. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein, Blood 1996, vol. 88, pp. 3091-3100.
Castaigne et al., Blood 1990, vol. 76, pp. 1704-1709.
Chambault-Guerin et al., 2000, Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells, Neuroreport vol. 11(2):389-393.
Chen et al. 2000, Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene, Cancer Res. 60:1035-1042.
Chen et al. 1999, Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol. 162:3212-3219.
Chu et al., 1994, Adjuvant-fre in vivo targeting: Antigen delivery by alpha 2-macroglobulin enhances antibody formation, J. Immunol 152(4):1538-1545.
Chu et al. 1994, Alpha 2-macroglobulin: a sensor for proteolysis, Ann. NY Acad. Sci 737:291-307.
Chu et al. 1994, Alpha 2-macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation, Lab. Invest. 71(6):792-812.
Chu et al. 1993, Receptor-mediated antigen delivery into macrophages: Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells, J. Immunol. 150(1):48-58.
Craig et al. 1993, Chaperones: helpers along the pathways to protein folding, Scinece 260:1902-1903.
Curley et al., 1995, Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann. Surg. 222(3):375-383.
Dazzi et al. 1999, Donor lymphocyte inf
Canella Karen
University of Connecticut
Wolf Greenfield & Sacks P.C.
LandOfFree
Using heat shock proteins to improve the therapeutic benefit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Using heat shock proteins to improve the therapeutic benefit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using heat shock proteins to improve the therapeutic benefit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289389